Online citations, reference lists, and bibliographies.

Importance Of Intensive Blood Pressure Control In Type 2 Diabetes: Mechanisms, Treatments And Current Guidelines

M. Marre
Published 2020 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Observational and interventional studies have shown that intensified blood pressure (BP) reduction can benefit people with diabetes. Because of their special haemodynamic properties, renin‐angiotensin‐aldosterone system (RAAS) blockers are recommended. The results of the BP arm of the ADVANCE study strongly support the recently updated European Society of Cardiology/European Association of Diabetes recommendations for the treatment of BP in people with diabetes, which recommend a target systolic/diastolic BP of 130/80 mmHg with few exceptions, and a fixed combination of an RAAS blocker with a diuretic or a calcium channel blocker as first‐line treatment.
This paper references
10.1056/NEJMOA011161
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
B. Brenner (2001)
10.2337/diacare.16.2.434
Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention Trial
J. Stamler (1993)
10.1056/NEJM198407123110204
Predicting diabetic nephropathy in insulin-dependent patients.
C. Mogensen (1984)
10.1016/0002-8703(91)90436-L
Doxazosin therapy in the treatment of diabetic hypertension.
M. Feher (1991)
10.1093/ndt/gfy197
Glycosuria amount in response to hyperglycaemia and risk for diabetic kidney disease and related events in Type 1 diabetic patients.
Charlyne Carpentier (2018)
10.1093/ndt/gfx071
T-cadherin gene variants are associated with nephropathy in subjects with type 1 diabetes
A. Nicolas (2017)
10.1016/S0084-3741(09)79281-9
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes
S. Schinner (2009)
10.1097/HCO.0000000000000173
Dual renin–angiotensin system blockade and outcome benefits in hypertension: a narrative review
J. Mann (2015)
10.1038/SJ.KI.5001580
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.
K. J. Schjoedt (2006)
10.1056/NEJMoa1009492
Eplerenone in patients with systolic heart failure and mild symptoms.
F. Zannad (2011)
10.1056/NEJM200001203420301
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
S. Yusuf (2000)
10.1056/NEJMc1600827
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
M. Fischereder (2016)
10.1016/S0140-6736(98)04311-6
Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial
L. Hansson (1998)
10.1056/NEJMoa1811744
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
V. Perkovic (2019)
10.1097/00132586-200006000-00059
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
B. Pitt (2000)
10.1136/bmj.297.6656.1092
Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria.
M. Marre (1988)
10.1007/s00125-018-4654-7
Development of SGLT1 and SGLT2 inhibitors
Timo Rieg (2018)
10.1056/NEJMoa1515920
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
C. Wanner (2016)
10.2174/1381612823666170609084436
Management of Blood Pressure and Heart Rate in Patients with Diabetes Mellitus.
I. Gouni-Berthold (2017)
10.1093/eurjhf/hfr051
Influence of order and type of drug (bisoprolol vs. enalapril) on outcome and adverse events in patients with chronic heart failure: a post hoc analysis of the CIBIS‐III trial
C. Funck-Brentano (2011)
10.1161/CIRCULATIONAHA.113.005081
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
D. Z. I. Cherney (2014)
10.1080/00325481.2018.1423852
Canagliflozin and cardiovascular and renal events in type 2 diabetes
R. Guthrie (2018)
10.1016/B978-1-4160-6193-9.10044-2
Inherited Disorders of the Renal Tubule
A. Bonnardeaux (2012)
10.1136/bmj.306.6871.175
Comparison of reduction in microalbuminuria by enalapril and hydrochlorothiazide in normotensive patients with insulin dependent diabetes.
M. Hallab (1993)
10.1001/jama.2014.18574
Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis.
C. Emdin (2015)
10.1161/01.CIR.96.9.3072
Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats.
J. Ménard (1997)
10.1056/NEJMoa1203858
Basal insulin and cardiovascular and other outcomes in dysglycemia.
H. Gerstein (2012)
10.1093/eurheartj/ehy339
2018 ESC/ESH Guidelines for the management of arterial hypertension.
B. Williams (2018)
10.1093/eurheartj/ehy686
Corrigendum to: 2018 ESC/ESH Guidelines for the management of arterial hypertension.
(2019)
Effects of beta-blockers on glucose and lipid metabolism
VA Fonseca (2010)
10.1172/JCI112521
Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.
R. Zatz (1986)
10.1111/j.1464-5491.2012.03585.x
Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo‐controlled crossover study
S. E. Nielsen (2012)
10.1056/NEJMoa1407963
Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
S. Zoungas (2014)
10.1016/S0140-6736(03)14286-9
Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
K. Fox (2003)
10.1016/j.freeradbiomed.2015.04.002
Allelic variations in the CYBA gene of NADPH oxidase and risk of kidney complications in patients with type 1 diabetes.
T. Patente (2015)
10.1161/HYPERTENSIONAHA.111.189589
Differential Effects of Nebivolol and Metoprolol on Insulin Sensitivity and Plasminogen Activator Inhibitor in the Metabolic Syndrome
K. Ayers (2012)
The Italian Microalbuminuria Study
IDDM (1998)
10.1056/NEJMoa0802987
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
A. Patel (2008)
10.1111/dom.13627
Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study
A. Norhammar (2019)
10.1097/MNH.0b013e32835abb52
The insulin receptor and the kidney
L. Hale (2013)
10.2337/dc17-1096
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
S. Inzucchi (2017)
10.1371/journal.pone.0096916
Manganese Superoxide Dismutase (SOD2) Polymorphisms, Plasma Advanced Oxidation Protein Products (AOPP) Concentration and Risk of Kidney Complications in Subjects with Type 1 Diabetes
K. Mohammedi (2014)
10.2337/diacare.21.1.104
Effects of Lisinopril and Nifedipine on the Progression to Overt Albuminuria in IDDM Patients With Incipient Nephropathy and Normal Blood Pressure
G. Crepaldi (1998)
The effect of spironolactone on morbidity and 40 MARRE mortality in patients with severe heart failure
B Pitt (1999)
10.1152/ajprenal.1983.244.2.F185
Mechanism of diuresis following acute modest hyperglycemia in the rat.
R. Blantz (1983)
10.1056/NEJMOA1812389
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Declare–Timi Investigators (2019)
10.1001/jama.2015.10081
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
G. Bakris (2015)
10.1016/S0895-7061(98)00077-6
Microalbuminuria and prevention of renal insufficiency and cardiovascular diseases.
M. Marre (1998)
10.1056/NEJMOA065061
Effect of ramipril on the incidence of diabetes.
J. Bosch (2006)
10.1016/S0140-6736(99)12323-7
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy
Heart Outcomes Prevention Evaluation Study Investigators (2000)
10.1056/NEJMoa1501352
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
J. Green (2015)
10.1007/BF00252649
The effect of insulin on renal sodium metabolism
R. DeFronzo (2004)
10.1097/01.HJH.0000133733.32125.09
Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR* study
M. Marre (2004)
10.2337/dc14-1958
Liraglutide Promotes Natriuresis but Does Not Increase Circulating Levels of Atrial Natriuretic Peptide in Hypertensive Subjects With Type 2 Diabetes
J. Lovshin (2014)
10.1016/S0140-6736(97)05381-6
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension
J. Staessen (1997)
10.1056/NEJM199209103271103
Relation of skin capillary pressure in patients with insulin-dependent diabetes mellitus to complications and metabolic control.
D. Sandeman (1992)
Blood pressure lowering in type 2 diabetes: a systematic review and metaanalysis
CA Emdin (2015)
10.1161/CIRCULATIONAHA.110.016337
Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose: Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials
S. Bangalore (2011)
10.1046/J.1523-1755.2000.07705.X
The missing link: a single unifying mechanism for diabetic complications.
T. Nishikawa (2000)
10.1016/j.amjmed.2008.09.038
Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials.
D. Wald (2009)
10.1136/bmj.317.7160.703
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
M. R. Stearne (1998)
10.1016/S0140-6736(98)07019-6
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
UK Prospective Diabetes Study Group (1998)
10.1001/jama.2019.13772
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial.
J. Rosenstock (2019)
10.7326/0003-4819-150-9-200905050-00006
A new equation to estimate glomerular filtration rate.
A. Levey (2009)
10.1042/CS1040039
Effects of inhibition of ATP-sensitive potassium channels on metabolic vasodilation in the human forearm.
H. Farouque (2003)
10.1056/NEJM199909023411001
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
B. Pitt (1999)
10.1056/NEJMoa1001121
Effect of valsartan on the incidence of diabetes and cardiovascular events.
J. McMurray (2010)
10.1136/bmj.321.7274.1440
Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study
C. Mogensen (2000)
10.1016/S0140-6736(02)11911-8
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
Prospective Studies Collaboration (2002)
10.1111/j.1475-097X.2004.00580.x
Forearm vascular reactivity is differentially influenced by gliclazide and glibenclamide in chronically treated type 2 diabetic patients
T. Wascher (2005)
10.1016/S0026-0495(00)80079-7
Gliclazide scavenges hydroxyl and superoxide radicals: an electron spin resonance study.
Y. Noda (2000)
10.1001/jama.2018.18269
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
J. Rosenstock (2019)
10.1056/NEJMoa1208799
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Hans‐Henrik Parving (2012)
Prospective studies collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies (vol 360, pg 1903, 2002)
S. Lewington (2003)
10.2337/db14-1852
Plasma Adrenomedullin and Allelic Variation in the ADM Gene and Kidney Disease in People With Type 2 Diabetes
G. Velho (2015)
10.1186/s12933-014-0163-2
Plasma extracellular superoxide dismutase concentration, allelic variations in the SOD3 gene and risk of myocardial infarction and all-cause mortality in people with type 1 and type 2 diabetes
K. Mohammedi (2015)
10.1056/NEJMoa1511939
A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
J. Wright (2015)
10.1093/eurheartj/ehz486
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
F. Cosentino (2019)
10.1016/S0140-6736(98)07037-8
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
UK Prospective Diabetes Study Group (1998)
Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.
J. Staessen (1997)
10.1056/NEJMoa1307684
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
B. Scirica (2013)
10.1056/NEJM198209093071104
Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease.
B. Brenner (1982)
10.1111/dom.13280
Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study
G. P. Fadini (2018)
Diuretic and natriuretic effects of nifedipine on isolated perfused rat kidneys.
M. Marre (1982)
10.1016/S0140-6736(08)61236-2
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
J. F. Mann (2008)
10.2337/dc17-1406
Mortality Reduction Associated With β-Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes
Klaus K. Witte (2017)
10.1056/NEJMoa0806359
Long-term follow-up after tight control of blood pressure in type 2 diabetes.
R. Holman (2008)
10.1016/S0140-6736(02)11911-8
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
S. Lewington (2002)
10.1111/dom.12654
Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin‐angiotensin blockers
H. L. Heerspink (2016)
10.1056/nejm199401133300225
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
A. Fournier (1994)
10.2337/dc10-2415
Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
R. Wing (2011)
10.1016/S0145-4145(10)79830-0
Combination Therapy Versus Monotherapy in Reducing Blood Pressure: Meta-analysis on 11,000 Participants from 42 Trials
W. Elliott (2010)
10.1681/ASN.2008121270
Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes.
T. Ninomiya (2009)
10.1136/jnnp-2014-307856
Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial
H. Arima (2014)
10.1111/dom.12651
Short‐term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial
J. Skov (2016)
10.1056/NEJMoa1305889
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
W. White (2013)
10.1136/bmj.295.6594.391
Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria.
P. Winocour (1987)
10.1097/01.ASN.0000016441.41118.57
Salt-sensitivity of proximal reabsorption alters macula densa salt and explains the paradoxical effect of dietary salt on glomerular filtration rate in diabetes mellitus.
V. Vallon (2002)
10.1046/J.1365-2125.2002.161311.X
The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.
M. G. Wulffelé (2004)
10.1056/NEJMoa0801317
Telmisartan, ramipril, or both in patients at high risk for vascular events.
S. Yusuf (2008)
10.1016/j.semerg.2015.12.009
[A randomized trial of intensive versus standard blood pressure control].
J. A. Divisón Garrote (2016)
Effect of modest hyperglycemia on tubuloglomerular feedback activity.
R. Blantz (1982)
10.1007/s40620-014-0136-2
Nitric oxide in the normal kidney and in patients with diabetic nephropathy
P. Tessari (2014)
10.1056/NEJM199311113292004
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.
E. Lewis (1993)
10.1136/bmj.294.6585.1448
Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria.
M. Marre (1987)
10.1007/s00125-013-3057-z
Catalase activity, allelic variations in the catalase gene and risk of kidney complications in patients with type 1 diabetes
K. Mohammedi (2013)
10.1210/en.2013-1934
GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.
C. Pyke (2014)
10.2337/db08-0057
Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes
J. Forbes (2008)
Heart Outcomes Prevention
Investigators Study (2000)
10.1056/NEJMoa1812389
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. Wiviott (2019)
10.1056/NEJMc1611289
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
L. Correia (2016)
10.1016/S0006-291X(84)80241-7
Gating and blocking of calcium channels by dihydropyridines in the pancreatic B-cell.
F. Malaisse-Lagae (1984)
10.1016/S0002-9149(98)00752-8
Treatment of isolated systolic hypertension in the elderly: further evidence from the systolic hypertension in Europe (Syst-Eur) trial.
J. Staessen (1998)
10.1016/S0140-6736(07)61303-8
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial
A. Patel (2007)
10.1056/NEJMoa1001286
Effects of intensive blood-pressure control in type 2 diabetes mellitus.
W. Cushman (2010)
10.1056/NEJMOA011303
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
Edmund J. Lewis (2001)
10.1093/eurheartj/ehz687
The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
P. Grant (2019)
How to cite this article: Marre M. Importance of intensive blood pressure control in type 2 diabetes: Mechanisms, treatments and current guidelines
(2020)
10.1016/j.metabol.2015.10.004
Glutathione peroxidase-1 gene (GPX1) variants, oxidative stress and risk of kidney complications in people with type 1 diabetes.
K. Mohammedi (2016)
10.1016/S0140-6736(05)67185-1
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled tri
B. Dahlöf (2005)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar